# Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack

> **NCT04304534** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 1601 (actual)

## Conditions studied

- Acute Myocardial Infarction

## Interventions

- **DRUG:** BAY2433334
- **OTHER:** BAY2433334 matching placebo

## Key facts

- **NCT ID:** NCT04304534
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-17
- **Primary completion:** 2022-02-21
- **Final completion:** 2022-02-21
- **Target enrollment:** 1601 (ACTUAL)
- **Last updated:** 2023-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04304534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04304534, "Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04304534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*